Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Nutriband and Kindeva to Co-Develop Aversa Fentanyl Abuse-Deterrent Patch
Details : Nutriband is partnering with Kindeva to develop Aversa Fentanyl which combines Nutriband’s Aversa abuse-deterrent technology with Kindeva’s FDA-approved fentanyl patch.
Product Name : Aversa Fentanyl
Product Type : Controlled Substance
Upfront Cash : Undisclosed
February 13, 2025
Lead Product(s) : Fentanyl
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Nutriband Provides Product Development Update for its Lead Product Aversa Fentanyl
Details : Aversa fentanyl abuse-deterrent transdermal technology can be utilized to incorporate aversive agents into transdermal patches to prevent the abuse, diversion, misuse, & accidental exposure of drugs.
Product Name : Aversa
Product Type : Controlled Substance
Upfront Cash : Inapplicable
June 20, 2024
Lead Product(s) : Fentanyl
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Nutriband Raises $8.4M for Aversa® Fentanyl Patch FDA Submission
Details : Net proceeds will fund the development of AVERSA Fentanyl, a potential first abuse-deterrent opioid patch to reduce misuse and accidental exposure risks with transdermal fentanyl.
Product Name : Aversa
Product Type : Controlled Substance
Upfront Cash : Undisclosed
April 24, 2024
Nutriband Inc. Announces $8.4M Private Placement
Details : The primary use of proceeds will be for completing the remaining clinical development of AVERSA Fentanyl and submission of its NDA with the FDA for marketing approval.
Product Name : Aversa
Product Type : Controlled Substance
Upfront Cash : Undisclosed
April 19, 2024
Nutriband Provides Overview for AVERSA(R) Fentanyl Transdermal Patch
Details : Aversa (fentanyl) utilizes abuse-deterrent transdermal technology with aversive agents to prevent drug abuse, diversion, and accidental exposure.
Product Name : Aversa
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 27, 2024
Lead Product(s) : Fentanyl
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Financing
Details : The net proceeds will be used to fund the development and regulatory submission process for the Company's patented lead product platform, AVERSA™ Fentanyl, an abuse-deterrent fentanyl transdermal system.
Product Name : Aversa
Product Type : Controlled Substance
Upfront Cash : Undisclosed
July 14, 2023
Lead Product(s) : Fentanyl
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : Fentanyl
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Kindeva Drug Delivery
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AVERSA™ (fentanyl) combines Nutriband’s proprietary AVERSA™ abuse-deterrent transdermal technology and Kindeva’s FDA-approved transdermal fentanyl patch system.
Product Name : Aversa
Product Type : Controlled Substance
Upfront Cash : Inapplicable
April 04, 2023
Lead Product(s) : Fentanyl
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Kindeva Drug Delivery
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fentanyl
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Financing
Details : The financing will be used for commercialising AVERSA™ Fentanyl, an abuse-deterrent fentanyl transdermal system. AVERSA™ Fentanyl contains Nutriband's proprietary transdermal abuse deterrent technology.
Product Name : Aversa
Product Type : Controlled Substance
Upfront Cash : Undisclosed
March 28, 2023
Lead Product(s) : Fentanyl
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : Fentanyl
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Aversa (fentanyl) abuse deterrent technology can be utilized to incorporate aversive agents into transdermal patches to prevent the abuse, diversion, misuse and accidental exposure of drugs with abuse potential such as opioids used to treat moderate to s...
Product Name : Aversa
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 12, 2022
Lead Product(s) : Fentanyl
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fentanyl
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Aversa (fentanyl) is an abuse deterrent transdermal technology that incorporates aversive agents to prevent the abuse, diversion, misuse and accidental exposure of drugs with abuse potential, specifically opioids.
Product Name : Aversa
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 08, 2022
Lead Product(s) : Fentanyl
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable